| Document |
Document Title |
|
WO/2024/079276A1 |
The present invention relates to a method for synthesising a photolytically degradable compound, the method comprising defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound ...
|
|
WO/2023/122242A1 |
A method of attaching an azide moiety to a biomolecule. The method entails contacting a biomolecule in a solution with an azide and an oxidizing agent, for a time and at a temperature wherein at least one azide moiety is covalently bonde...
|
|
WO/2023/109157A1 |
Provided in the present invention are procaine penicillin and a preparation method therefor, and an impurity and an impurity control method, wherein the content of RRT0.24 impurity in the procaine penicillin is less than 0.13%. The prepa...
|
|
WO/2023/084455A1 |
Pharmaceutical combinations comprising a lactivicin such as L TV-17 of formula (I) and one or more beta-lactamase inhibitors such as avibactam are disclosed. Lactivicin L TV-17 in combination with the beta lactamase inhibitor avibactam a...
|
|
WO/2023/007325A1 |
A metallo-β-lactamase (MBL) inhibitor of general formula (I) C-A-L (I) in which: C is a funtionalised aza-cycloalkane zinc chelating moiety, L is a β-lactam moiety which may be functionalised, and A is a C1-C10 linear or cyclic linker,...
|
|
WO/2022/239872A1 |
The present invention provides: a compound represented by formula (I), formula (II), or formula (IV), or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition that is to be used for inhibiting metallo-β-lactamase ...
|
|
WO/2022/217364A1 |
A new class of antibiotics, namely, mercaptoacetophenone aminohydrazones, their analogues, their method of preparation, their salts, and their use in cases of bacterial infections, either alone or with other compounds.
|
|
WO/2022/208356A1 |
Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with P-lactamase inhibitor...
|
|
WO/2021/228009A1 |
Disclosed in the present invention are a piperacillin magnesium compound, a composition, a preparation method and use. The preparation method comprises: providing a piperacillin-containing reactant, and providing a magnesium compound; pe...
|
|
WO/2021/137835A1 |
The present invention relates to new penicillin derivatives having the potential of being effectively used against microbes and bacteria which have attained resistance in order to perform many useful pharmaceutical activities such as ant...
|
|
WO/2021/094410A1 |
The invention relates to a complex comprising an antibiotic substance and a nucleophilic derivatization reagent, compositions comprising the complex, kits comprising complex or composition, as well as uses of the complex or composition.
|
|
WO/2021/094409A1 |
The present invention relates to derivatization of antibiotic analytes as well as methods of determining the amount or concentration of derivatized antibiotic analytes in an obtained sample.
|
|
WO/2021/066149A1 |
The problem addressed by the present invention is to provide a pharmaceutical composition and kit that exhibit strong antibacterial activity against gram-negative bacteria and/or drug-resistant, gram-negative bacteria. This pharmaceutica...
|
|
WO/2020/251953A1 |
Disclosed herein, inter alia, are streptogramin compounds, compositions, and methods of use thereof. A method of treating an infectious disease, the method including administering to a subject in need thereof an effective amount of a com...
|
|
WO/2020/057592A1 |
Beta-lactam compounds to detect carbapenemases or microbial carbapenem resistance are disclosed. The compounds contain a chemical probe. Upon hydrolysis by carbapenemases, the compounds undergo intramolecular rearrangement and release th...
|
|
WO/2019/194306A1 |
The problem addressed by the present invention is to provide compounds and pharmaceutical compositions that demonstrate strong antibacterial activity against gram-negative bacteria and drug-resistant gram-negative bacteria. Compounds rep...
|
|
WO/2019/155266A1 |
This invention is about the discovery of a new novel compound as an antibiotic to stop this potential resistance problem completely. With Organic Chemistry studies and methods and other modified antibiotics, adding a flavonoid group to v...
|
|
WO/2019/100544A1 |
A novel method for preparing a key intermediate, a 6α-bromopenicillanic sulfoxide acid diphenylmethyl ester, in tazobactam analysis. The method comprises the following steps: dissolving a 6α-bromopenicillanic sulfoxide acid in an organ...
|
|
WO/2019/070052A1 |
The present invention addresses the problem of providing a compound and pharmaceutical composition which have strong antibacterial activity against gram-negative bacteria and drug-resistant strains thereof. The compound according to the ...
|
|
WO/2018/233477A1 |
The present invention discloses a method for removing a carboxyl and hydroxyl protecting group of a β-lactam compound. The method is removing a carboxyl and/or hydroxyl protecting group from a protected β-lactam compound under the acti...
|
|
WO/2018/207165A1 |
The present disclosure relates to a new class of antimicrobial agents. In particular, this disclosure provides the identification and characterization of novel spiro-lactam compoundsas anti-HIV/AIDS and anti-malarial agents. Furthermore,...
|
|
WO/2018/071358A1 |
Antibacterial agents against D,D- and L,D-transpeptidases are disclosed. Pharmaceutical compositions and methods of using the same also are disclosed.
|
|
WO/2018/030840A1 |
The present invention relates to various compounds capable of temporarily firmly hardening a soft tissue for suture surgery of the soft tissue. The compounds according to the present invention can temporarily increase the hardness or ten...
|
|
WO/2017/153892A1 |
A synthesis process of precursors of derivatives of beta-lactam compounds, said beta-lactam compounds being selected from 6-aminopenicillanic acid and 7-aminocephalosporanic acid, preferably 6-aminopenicillanic acid, comprising the follo...
|
|
WO/2017/117882A1 |
Disclosed is a pharmaceutical composition of piperacillin sodium and sulbactam sodium, comprising 2-4 parts by weight of piperacillin sodium and 1 part by weight of sulbactam sodium having a specific rotation of +230° to +235°. By opti...
|
|
WO/2017/096472A1 |
Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or...
|
|
WO/2017/059062A1 |
Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti- angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are no...
|
|
WO/2017/021390A1 |
The present invention relates to the hemi sulfuric acid salt of methyl (R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetate, also trivially referred to as the hemi sulfuric acid salt of D-dihydrophenylglycine methyl ester, to a method for the ...
|
|
WO/2016/175223A1 |
Provided are the following: compounds having a powerful anti-bacterial spectrum against a variety of bacteria, including gram-negative bacteria and gram-positive bacteria; and pharmaceutical compositions having antibacterial activity aga...
|
|
WO/2016/139373A1 |
Molecular storage materials for incorporating small molecules in solid matrices may find applications in structure elucidation, decontamination, and slow release of active ingredients. The syntheses of 1,3,5,7-tetrakis(2,4-dimethoxypheny...
|
|
WO/2016/046055A1 |
The present invention relates to the hemi sulfuric acid salt of D-phenylglycine methyl ester, to a method for the preparation of said salt and to the use of said salt in the enzymatic synthesis of antibiotics and of D-phenylglycine methy...
|
|
WO/2016/027262A1 |
A compound, comprising: an Fe(III)-binding and/or Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; and daptomycin covalently bound to the linker, or, if no linker is present, then to the siderop...
|
|
WO/2015/173378A2 |
A method of forming a compound of formula (IIIa); wherein: R1 in each occurrence is independently selected from H, halogen, amino, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl; R2 in each occurrence is independently selected from H, halogen...
|
|
WO/2015/067787A1 |
A crystalline compound of formula (I): Formula (I). The compound of formula (I) is a β-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.
|
|
WO/2015/032711A1 |
The present invention relates to amoxicillin trihydrate compositions having a surface area of from 1.0 to 2.5 m2.g-1 that are free of organic contaminants such as dichloromethane, isopropanol, pivalic acid and triethyl amine and that hav...
|
|
WO/2015/021692A1 |
Provided is a bacteria culture medium, wherein the culture medium is prepared by adding one or more β-lactam antibiotics and/or salts thereof to an ordinary bacteria culture medium in advance, wherein the β-lactam antibiotics and/or sa...
|
|
WO/2015/012158A1 |
A method for providing a vascular system in biological tissue in vitro, the method comprising cocultivation of the biological tissue with vascular cells and mesenchymal cells. Biological tissue in which a vascular system has been provide...
|
|
WO/2014/171971A1 |
An artificial tris-catecolate siderophore with a tripodal backbone and its conjugates with ampicillin and amoxicillin were synthesized. Both conjugates exhibited significantly enhanced in vitro antibacterial activities against Gram-negat...
|
|
WO/2014/072843A1 |
The present invention relates to a process for the preparation of isoxazolyl penicillins from sugarcane juice. The invention focuses on in-situ synthesis of isoxazolyl penicillins without isolation of the intermediates like Penicillin G ...
|
|
WO/2014/040280A1 |
Provided in the present invention are a cocrystal of piperacillin sodium and sulbactam sodium and a preparation method therefor, as well as pharmaceutical compositions containing the same and uses thereof in treating infections caused by...
|
|
WO/2014/037893A1 |
The present invention relates to an improved process for the preparation of Tazobactam of formula (I) having reduced content of cresol. (Formula I) (I)
|
|
WO/2013/109927A2 |
It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide ("AMP") and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain...
|
|
WO/2013/010102A2 |
The present invention provides compositions and methods for the administration and targeted delivery, release and/or formation of a drug compound from a halogenated phenol starting compound of the present invention at site(s) within the ...
|
|
WO/2013/000277A1 |
Provided is a method for preparing ticarcillin disodium with less side reaction and strong controllability in mild reaction condition using fewer steps, which comprises (1) reacting 3-thiophene malonic acid with N-hydroxyl succinimide in...
|
|
WO/2012/164355A1 |
Disclosed is an improved process for the preparation of isoxazolyl penicillins of formula (I), wherein X1 and X2 can be independently selected from the group comprising hydrogen, chlorine or fluorine, and its pharmaceutically suitable sa...
|
|
WO/2012/105596A1 |
[Problem] To provide a method for the fluorescent labeling of a protein that can even be used for the fluorescent labeling of a biological molecule (protein) in vivo. [Solution] A method for the fluorescent labeling of a target protein, ...
|
|
WO/2012/000421A1 |
Disclosed are gossypol derivatives, preparation methods and uses thereof in the manufacture of antitumor medicaments. Pharmaceutical compositions containing the said gossypol derivatives and preparation methods thereof are also disclosed.
|
|
WO/2011/158133A1 |
An improved process for preparing sterile amoxicillin and an alkali metal salt thereof, wherein the said process involves the steps of: i) dissolving amoxicillin trihydrate in methyl acetate, methanol and triethylamine; ii) Passing the r...
|
|
WO/2011/040386A1 |
Disclosed is a novel crystal of piperacillin sodium monohydrate, which has diffraction angles represented by 2θ of 6.6, 10.9, 14.6, 17.0, 18.2, 19.8 and 24.9° in powder X-ray diffraction. The crystal has a low analogous substance conte...
|
|
WO/2010/095617A1 |
Disclosed is a process for producing a 4-chloroazetidinone compound, which is a compound useful as an intermediate for the synthesis of a carbapenem antibiotic, with high efficiency and in a high yield. Also disclosed is an intermediate...
|
